乳康口服液对乳腺增生大鼠作用机制研究  

Action Mechanism of Rukang Oral Liquid in Rats with Hyperplasia of Mammary Glands

作　　者：吴晓燕[1] 瞿发林[1] 许立[2] 

机构地区：[1]解放军第102医院制剂中心,江苏常州213000 [2]南京中医药大学

出　　处：《中国药师》2016年第4期647-651,共5页China Pharmacist

摘　　要：目的:对乳康口服液治疗乳腺增生的作用机制做进一步研究。方法:实验分为6组:正常对照组、模型对照组、三苯氧胺组和乳康口服液低、中、高剂量组,用苯甲酸雌二醇注射液和黄体酮注射液制备大鼠乳腺增生模型后再予相应药物治疗。给药结束后应用ELISA法测定雌激素受体(ER)、孕激素受体(PR)、P53、Oct4的浓度,用Western blot检测乳腺组织ER、PR、P53和Oct4表达,用荧光定量PCR法检测促性腺激素释放激素(GnRH)及其受体(GnRHR)的表达,原位杂交法检测乳腺组织端粒酶的表达。结果:乳康口服液可以降低血清和乳腺组织中ER、PR的表达量(P<0.01),降低P53、端粒酶及Oct4的表达(P<0.01),降低下丘脑GnRH及垂体GnRH受体表达(P<0.01),从多方面逆转乳腺增生,发挥其治疗作用。结论:乳康口服液可通过抑制降低血清和乳腺组织中ER、PR的表达,下丘脑GnRH及垂体GnRH受体表达等途径发挥药效学。同时乳康口服液可能会通过降低与乳腺癌发生相关的三个相关标志物P53、端粒酶和Oct4表达量来发挥预防乳腺增生发展为乳腺癌的功效。Objective： To study the action mechanism of Rukang oral liquid in rats with hyperplasia of mammary glands. Methods： The rats were randomly divided into six groups： the normal group,the model group,tamoxifen group,low,medium and high dose of Rukang oral liquid groups. The model of hyperplasia of mammary glands was induced by estradiol benzoate injection and progesterone injection. After the administration,ELISA was used to detect the serum concentrations of ER,PR,P53 and Oct4,Western blot was used to detect the expression of ER,PR,P53 and Oct4 in breast tissue,a fluorescence quantitative PCR method was used to detect the expression of GnRH,GnRHR,and the expression of telomerase in breast tissue was detected by in situ hybridization. Results： Rukang oral liquid could reduce the expression of ER and PR in serum and breast tissue（ P〈0.01）,reduce the expression of P53,telomerase and Oct4（ P〈0.01）,and decrease the expression of GnRH in hypothalamus and pituitary,which could reverse the hyperplasia of mammary glands and played the role effectively（ P〈0.01）. Conclusion： Rukang oral Liquid can reduce the expression of ER and PR in serum and breast tissue,and decrease the expression of GnRH in hypothalamus and pituitary to play the role in the treatment of hyperplasia of mammary glands. Rukang oral Liquid may prevent breast hyperplasia from developing into breast cancer through reducing the expression of three related markers P53,telomerase and Oct4.

关 键 词：乳康口服液 乳腺增生 乳腺癌 作用机制 

分 类 号：R285.5[医药卫生—中药学]